Mushtaq Ali H, Rasheed Abdulrahman W, Jamil Mouhamad G, Maghrabi Khalid, Khoja Osama, Sajid Muhammad R, Tamim Hani, Hijazi Mohammad, Owaidah Tarek
Al Faisal University Riyadh, Saudi Arabia.
Department of Internal Medicine, Cleveland Clinic Foundation Cleveland, Ohio, The United States of America.
Am J Blood Res. 2023 Dec 25;13(6):198-206. doi: 10.62347/GPME5540. eCollection 2023.
Heparin-induced thrombocytopenia (HIT) is an extremely serious and potentially fatal condition that can develop in patients taking heparin-based medications, such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). The incidence and risk factors for HIT in critically ill patients, however, are not well defined.
We retrospectively collected data on HIT test results, route of heparin administration, age, sex, heparin type (UFH or LMWH), and date of illness from patients admitted to the intensive care unit (ICU) and regular nursing floor (non-ICU) at our hospital between January 2011 and December 2014. We screened patients for HIT using the 4T score and confirmed the diagnosis through laboratory testing (direct enzyme immunoassay immunoglobulin G [IgG] or a platelet-activating antibody).
We screened a total of 946 patients, 56 (5.9%) of whom were positive for HIT. Among 776 patients receiving UFH and 180 receiving LMWH, 2.8 and 6.6% developed HIT, respectively ( = 0.051). We then classified our patients into two groups: ICU, and non-ICU. In the non-ICU group (n = 317), 4 (2.7%) patients receiving LMWH and 25 (5.1%) receiving UFH were positive for HIT ( = 0.221). In the ICU group (n = 639), 1 (3.1%) patient receiving LMWH and 26 (9.1%) receiving UFH were positive for HIT ( = 0.249). The ICU group, therefore, had a higher cumulative incidence rate of HIT than the non-ICU group (8.5 vs. 4.5%).
HIT was more common in ICU patients than non-ICU patients and in more patients receiving UFH than LMWH, although the differences were not statistically significant. Early diagnosis and appropriate treatment are essential to prevent adverse outcomes in patients with HIT.
肝素诱导的血小板减少症(HIT)是一种极其严重且可能致命的疾病,可发生于使用基于肝素的药物(如普通肝素[UFH]或低分子肝素[LMWH])的患者中。然而,重症患者中HIT的发病率和危险因素尚不明确。
我们回顾性收集了2011年1月至2014年12月期间在我院重症监护病房(ICU)和普通护理病房(非ICU)住院患者的HIT检测结果、肝素给药途径、年龄、性别、肝素类型(UFH或LMWH)及发病日期等数据。我们使用4T评分筛选HIT患者,并通过实验室检测(直接酶免疫测定免疫球蛋白G[IgG]或血小板激活抗体)确诊。
我们共筛选了946例患者,其中56例(5.9%)HIT检测呈阳性。在776例接受UFH的患者和180例接受LMWH的患者中,分别有2.8%和6.6%发生了HIT(P = 0.051)。然后我们将患者分为两组:ICU组和非ICU组。在非ICU组(n = 317)中,4例(2.7%)接受LMWH的患者和25例(5.1%)接受UFH的患者HIT检测呈阳性(P = 0.221)。在ICU组(n = 639)中,1例(3.1%)接受LMWH的患者和26例(9.1%)接受UFH的患者HIT检测呈阳性(P = 0.249)。因此,ICU组的HIT累积发病率高于非ICU组(8.5%对4.5%)。
HIT在ICU患者中比非ICU患者更常见,接受UFH的患者比接受LMWH的患者更常见,尽管差异无统计学意义。早期诊断和适当治疗对于预防HIT患者的不良结局至关重要。